The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

The FDA has removed a boxed warning on medicines delivering a combinations of inhaled corticosteroid (ICS) and long-acting beta agonists (LABA) drugs. The FDA has removed a boxed warning of asthma ...

When added to ICS, tiotropium and LABAs perform similarly for asthma patients. What is the effect of ICS/LABA controller therapy on asthma in patients with persistent cold airway hyperresponsiveness, ...

The trials did show that ICS/LABA combination medicines were more effective in decreasing asthma attacks (e.g., the need to use oral corticosteroids) compared to ICS alone. This additional information ...

Photomicrograph of salivary gland of a person with Sjögren’s syndrome, characterized by the abnormal migration of of lymphocytes T and B. Here the lymphocytes T and B appear in mauve. Investigators ...

For patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment options include a long-acting beta-agonist (LABA) alone or a LABA combined with an inhaled corticosteroid ...

Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...

Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...